Xpert MRSA/SA Nasal

"Determining pre-operative carrier status of S. aureus, including MRSA, can be helpful in targeting patient treatment, including decolonization, shown to reduce post-operative SSIs. This is particularly important given the high economic burden of S. aureus infection among patients admitted for elective surgery."
-Professor Jan Kluytmans, MD
Professor of Medical Microbiology and Infection Control
VUmc, Amsterdam

Runs On: GeneXpert System

The Need

Current Testing Methodologies Don't Deliver
Staphylococcus aureus infections have been increasing in incidence and are reported to be the most common cause of surgical site infections:

• S. aureus colonized patients are up to 9 times more likely to develop surgical site infections than non-carriers
• Up to 80% of nosocomial S. aureus infections are caused by the patient's own flora
• Surgical site infections are associated with increases in length of hospital stay, costs, morbidity, and mortality

The Solution

Xpert^® MRSA/SA Nasal Benefits
Determination of S. aureus and MRSA carrier status is crucial in reducing the risk of post-operative infections:

• Rapid identification of patient carrier status optimizes pre-admission workflow and counseling
• Enables clinicians to consider enhanced pre and peri-operative patient management approaches, including decolonization
• Supports improved infection control and reduces the risk of cross infection

Impact

Impact of Pre-Surgical Screening on Post-Operative Infection Rates S. aureus can lead to more serious complications, especially in orthopaedic and cardiovascular procedures leading to poor patient outcomes which prolong hospital stay and costs.

Impact on Resource Utilization and Hospital Efficiencies Pre-surgical screening in combination with decolonization has been shown to reduce post-operative infection rates by up to 60%.